1. Home
  2. LYV vs ARGX Comparison

LYV vs ARGX Comparison

Compare LYV & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LYV
  • ARGX
  • Stock Information
  • Founded
  • LYV 2005
  • ARGX 2008
  • Country
  • LYV United States
  • ARGX Netherlands
  • Employees
  • LYV N/A
  • ARGX N/A
  • Industry
  • LYV Services-Misc. Amusement & Recreation
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • LYV Consumer Discretionary
  • ARGX Health Care
  • Exchange
  • LYV Nasdaq
  • ARGX Nasdaq
  • Market Cap
  • LYV 33.5B
  • ARGX 35.3B
  • IPO Year
  • LYV N/A
  • ARGX 2017
  • Fundamental
  • Price
  • LYV $136.31
  • ARGX $578.29
  • Analyst Decision
  • LYV Strong Buy
  • ARGX Strong Buy
  • Analyst Count
  • LYV 17
  • ARGX 20
  • Target Price
  • LYV $161.88
  • ARGX $698.22
  • AVG Volume (30 Days)
  • LYV 2.7M
  • ARGX 493.8K
  • Earning Date
  • LYV 07-29-2025
  • ARGX 05-08-2025
  • Dividend Yield
  • LYV N/A
  • ARGX N/A
  • EPS Growth
  • LYV 188.13
  • ARGX N/A
  • EPS
  • LYV 2.97
  • ARGX 15.94
  • Revenue
  • LYV $22,738,213,000.00
  • ARGX $2,643,062,000.00
  • Revenue This Year
  • LYV $13.11
  • ARGX $61.64
  • Revenue Next Year
  • LYV $8.80
  • ARGX $32.00
  • P/E Ratio
  • LYV $46.27
  • ARGX $32.97
  • Revenue Growth
  • LYV N/A
  • ARGX 82.13
  • 52 Week Low
  • LYV $86.81
  • ARGX $359.37
  • 52 Week High
  • LYV $157.75
  • ARGX $678.21
  • Technical
  • Relative Strength Index (RSI)
  • LYV 47.23
  • ARGX 47.86
  • Support Level
  • LYV $134.74
  • ARGX $566.31
  • Resistance Level
  • LYV $147.15
  • ARGX $584.90
  • Average True Range (ATR)
  • LYV 3.30
  • ARGX 13.21
  • MACD
  • LYV -1.13
  • ARGX 0.96
  • Stochastic Oscillator
  • LYV 18.22
  • ARGX 73.88

About LYV Live Nation Entertainment Inc.

Live Nation is the largest live entertainment company in the world, serving as a concert promoter, venue operator, and ticketing platform. In addition, the firm generates revenue from sponsorships and advertising. With offices in 45 countries, Live Nation promotes concerts globally and it owns, operates, or had exclusive booking rights to nearly 400 venues worldwide at the end of 2024, which the firm says makes it the second-largest operator of music venues globally. In 2024, Live Nation promoted nearly 55,000 events, drawing more than 150 million fans. Ticketmaster is a dominant global ticketing service, selling almost 640 million tickets in 2024.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: